{{noteTA
|G1 = ME
}}{{medical}}
{{Drugbox
| IUPAC_name =  
| image = Enbrel.jpg
| width = 153
<!-- Clinical data -->
| tradename = 恩博（Enbrel）
| Drugs.com = {{drugs.com|monograph|etanercept}}
| pregnancy_category =
| pregnancy_AU = B2
| pregnancy_US = B
| licence_EU = yes
| legal_status = 
| legal_AU = S4
| legal_UK = POM
| legal_US = ℞-only
| routes_of_administration = 皮下注射
<!-- Pharmacokinetic data -->
| bioavailability = 58–76% (SC)
| metabolism = [[单核吞噬细胞系统|单核吞噬细胞系统]]（推測）
| elimination_half-life = 70–132 hours
| excretion =
<!-- Identifiers -->
| CAS_number = 185243-69-0
| ATC_prefix = L04
| ATC_suffix = AB01
| PubChemSubstance = 10099
| DrugBank = DB00005
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = OP401G7OJC
| KEGG = D00742
| ChEMBL = 1201572
| ChemSpiderID = none
<!-- Chemical data -->
| C=2224 | H=3475 | N=621 | O=698 | S=36
| molecular_weight = 51234.9 g/mol
}}
'''Etanercept'''（商品名：'''恩博'''）是一種治療自體免疫疾病的[[生物治療|生物製劑]]，作用機轉為干擾{{tsl|en|tumor necrosis factor|腫瘤壞死因子}}（TNF，一種可溶性的發炎性細胞激素）的作用，為{{tsl|en|TNF inhibitor|腫瘤壞死因子抑制劑}}。美國食品衛生管理局已許可此藥物用於治療[[類風濕性關節炎|類風濕性關節炎]]、[[幼年特發性關節炎|幼年特發性關節炎]]、{{tsl|en|psoriatic arthritis|乾癬性關節炎}}、斑塊狀乾癬和[[强直性脊柱炎|强直性脊柱炎]]。[[肿瘤坏死因子-α|肿瘤坏死因子-α]]（TNF-α）是許多器官系統中發炎反應的調節中心，而自體免疫疾病是由過度的免疫反應造成，由於恩博能抑制TNF-α，因此具有治療此類疾病的潛力<ref name="titleTNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases - Nature Medicine">{{cite journal | vauthors = Feldmann M, Maini RN | title = Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases | journal = Nature Medicine | volume = 9 | issue = 10 | pages = 1245–50 | date = October 2003 | pmid = 14520364 | doi = 10.1038/nm939 }}</ref>。

恩博是一種由[[重組DNA|重組DNA]]製造的{{tsl|en|fusion protein|融合蛋白}}，將腫瘤壞死因子受體結合到IgG1抗體的恆定端。首先，科學家分別分離人類可溶性{{tsl|en|CD120|腫瘤壞死因子受體2}}（CD120，為TNF-α的受體）的DNA序列，以及人類[[IgG|免疫球蛋白IgG1]]的{{tsl|en|Fragment crystallizable region|可結晶區域片段|Fc}}區段的DNA序列，然後再把兩者的DNA序列結合，最後就能藉由結合的DNA表現出帶有腫瘤壞死因子受體的IgG1 Fc。1990年代早期[[布鲁斯·博伊特勒|布鲁斯·博伊特勒]]（之後任教於{{tsl|en|University of Texas Southwestern Medical Center at Dallas|達拉斯德州大學西南醫學中心|德州大學西南醫學中心}}）和他的同事首先合成了這種合成蛋白的原型，並發現他在生物體內仍有很好的活性，並能穩定的阻斷TNF的作用<ref>{{cite journal | vauthors = Peppel K, Crawford D, Beutler B | title = A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity | journal = The Journal of Experimental Medicine | volume = 174 | issue = 6 | pages = 1483–89 | date = December 1991 | pmid = 1660525 | pmc = 2119031 | doi = 10.1084/jem.174.6.1483 }}</ref><ref>{{cite journal | vauthors = Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B | title = Expression of a TNF inhibitor in transgenic mice | journal = Journal of Immunology | volume = 151 | issue = 10 | pages = 5699–703 | date = November 1993 | pmid = 7693816 | doi = 10.1073/pnas.91.1.215 }}</ref>。

這些研發者也為此合成蛋白申請了專利<ref>U.S. Patent number: 5,447,851</ref>，並將所有權利售予生技公司Immunex，該公司其後於2002年被[[安进|安进]]（Amgen）併購<ref name="title|| DukeMedNews || Arthritis Drug Effective for Depression in Psoriasis Sufferers">{{cite web |url=http://www.dukemednews.org/news/article.php?id=9419 |title=Arthritis Drug Effective for Depression in Psoriasis Sufferers |accessdate=2008-01-10 |archive-url=https://web.archive.org/web/20071020205003/http://www.dukemednews.org/news/article.php?id=9419 |archive-date=2007-10-20 |dead-url=yes }}</ref>。

恩博是一種大型分子，分子量150[[原子质量单位|kDa]]。它在結合到TNFα後能減少TNFα的作用，減少[[自體免疫性疾病|自體免疫性疾病]]中過度的發炎反應，例如[[强直性脊柱炎|强直性脊柱炎]]<ref name="pmid17389658">{{cite journal | vauthors = Braun J, McHugh N, Singh A, Wajdula JS, Sato R | title = Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly | journal = Rheumatology | volume = 46 | issue = 6 | pages = 999–1004 | date = June 2007 | pmid = 17389658 | doi = 10.1093/rheumatology/kem069 }}</ref>、[[幼年特發性關節炎|幼年特發性關節炎]]、[[銀屑病|乾癬]]、{{tsl|en|psoriatic arthritis|乾癬性關節炎}}、[[類風濕性關節炎|類風濕性關節炎]]和其他可能因TNF-α反應過度而引發的疾病。

== 醫療用途 ==
美國食品衛生管理局核准恩博用於：
*中度到重度[[類風濕性關節炎|類風濕性關節炎]]（RA，1998年11月）<ref>{{cite letter | first = Jay P.| last = Siegel | recipient = Sally Gould | subject = Approval of Etanercept for treatment of rheumatoid arthritis | date = {{date|1998-11-02|mdy}} | accessdate = {{date|2015-04-14|mdy}} | url = http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088659.pdf | publisher = Food and Drug Administration}}</ref>
*中度到重度多關節[[幼年特發性關節炎|幼年特發性關節炎]]（1999年5月）<ref>{{cite letter | first = Karen D. | last = Weiss | recipient = Sally Gould | subject = Approval of Etanercept for treatment of polyarticular course juvenile rheumatoid arthritis (JRA) | date = {{date|1999-05-27|mdy}} | accessdate = {{date|2015-04-14|mdy}} | url = http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088844.pdf | publisher = Food and Drug Administration}}</ref>
*{{tsl|en|Psoriatic Arthritis|乾癬性關節炎}}（2002年1月）<ref>{{cite letter | first = Karen D. | last = Weiss | recipient = Sally Gould | subject = Approval of Etanercept for treatment of psoriatic arthritis | date = {{date|2002-01-15|mdy}} | accessdate = {{date|2015-04-14|mdy}} | url = http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/etanimm011502L.htm | publisher = Food and Drug Administration}}</ref>
*[[强直性脊柱炎|强直性脊柱炎]]（AS，2003年7月）<ref>{{cite letter | first = Patricia | last = Keegan | recipient = Douglas Hunt | subject = Approval of Etanercept for treatment of ankylosing spondylitis | date = {{date|2003-07-24|mdy}} | accessdate = {{date|2015-04-14|mdy}} | url = http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103795-5123_Enbrel_approv.pdf | publisher = Food and Drug Administration}}</ref><ref>{{cite journal | vauthors = Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA | title = TNF-alpha inhibitors for ankylosing spondylitis | journal = The Cochrane Database of Systematic Reviews | volume = 4 | issue = 4 | pages = CD005468 | date = April 2015 | pmid = 25887212 | doi = 10.1002/14651858.CD005468.pub2 }}</ref>
*中度到重度[[銀屑病|乾癬]]（2004年4月）<ref>{{cite letter | first = Marc | last = Walton | recipient = Douglas Hunt | subject = Approval of Etanercept for treatment of moderate to severe plaque psoriasis | date = {{date|2004-04-30|mdy}} | accessdate = {{date|2015-04-14|mdy}} | url = http://www.accessdata.fda.gov/drugsatfda_docs/appletter/biologics/2004/103795_5149ltr.pdf | publisher = Food and Drug Administration}}</ref>

== 安全性 ==
2008年5月，[[美國食品藥物管理局|美國食品藥物管理局]]由於一些和恩博有關的嚴重感染，而對該藥物發出了{{tsl|en|Boxed warning|黑箱警告}}<ref name="Wyeth and Amgen">{{cite web|url=http://money.cnn.com/news/newsfeeds/articles/apwire/21965cf0a650a8b5897142bfcbccb427.htm |title=Wyeth and Amgen heighten warning of life-threatening infections on skin drug Enbrel |accessdate=2008-05-02 |archiveurl=https://web.archive.org/web/20080505133653/http://money.cnn.com/news/newsfeeds/articles/apwire/21965cf0a650a8b5897142bfcbccb427.htm |archivedate=2008-05-05 |deadurl=yes }}</ref>。一些報告指出，患者在使用恩博後引發嚴重的感染、[[敗血症|敗血症]]、甚至死亡，當中也包括了{{tsl|en|latent tuberculosis|潛伏性結核}}和[[乙型肝炎|乙型肝炎]]再活化而造成的感染<ref name="FDAReport">{{cite conference | url=http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety%20_revision2.pdf | title=Safety Update on TNF- α Antagonists: Infliximab and Etanercept | publisher=Food and Drug Administration | accessdate=2013-12-20 | pages=13–14}}</ref><ref name="titlePrescribing Information - ENBREL">{{cite web |url=http://www.enbrel.com/prescribing-information.jsp |title=Prescribing Information – Enbrel |accessdate=2008-01-10 |format= |website= |deadurl=yes |archiveurl=https://web.archive.org/web/20071014032450/http://enbrel.com/prescribing-information.jsp |archivedate=2007-10-14 }}</ref>。此外，也有在使用恩博後造成[[糞小桿線蟲|糞小桿線蟲]]過度感染的案例<ref>{{cite web | url=http://www.uptodate.com/contents/strongyloidiasis/abstract/67?utdPopup=true | title=UpToDate}}</ref>。

== 作用機轉 ==
此藥物可減少腫瘤壞死因子（TNF）的作用，因此為一種{{tsl|en|TNF inhibitor|TNF抑制劑}}，作為可以結合TNF並使之失去生理作用的{{tsl|en|decoy receptor|游離受體}}<ref>{{cite journal | vauthors = Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, Eivazi A, Kung J, Nguyen DH, Doberstein SK, Erard F, Ryffel B, Szymkowski DE | title = Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection | journal = Journal of Immunology | volume = 179 | issue = 3 | pages = 1872–83 | date = August 2007 | pmid = 17641054 | doi = 10.4049/jimmunol.179.3.1872 }}</ref>。腫瘤壞死因子α(TNF-α)是一種由[[淋巴细胞|淋巴细胞]]和[[巨噬细胞|巨噬细胞]]這兩種白血球分泌的[[细胞因子|細胞激素]]。可藉由吸引更多白血球到[[發炎|發炎]]處來媒介免疫反應，並藉由其他分子機制啟動和放大發炎反應，抑制此過程對於治療[[自體免疫性疾病|自體免疫性疾病]]相當重要。
TNF的[[受体_(生物化学)|受體]]則有兩種：一種附著在白血球細胞表面，與TNF結合後會引發白血球的反應，釋放其他細胞激素；另一種則是「可溶」的受體，在組織液中與TNF結合後會使之失去效用，稱為游離受體。此外，TNF受體分布在幾乎所有有核細胞的表面（紅血球因為沒有核，所以也沒有TNF受體）。而恩博便是模擬游離受體的抑制性作用，但與天然的游離受體不同的是，恩博不是一個單純的TNF受體，而是一種人工合成的融合蛋白，因此在血液中的半衰期大幅增加，能有更顯著且持久的生物效果<ref name="pmid16135466">{{cite journal | vauthors = Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS | title = Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer | journal = Journal of Clinical Oncology | volume = 23 | issue = 25 | pages = 5950–59 | date = September 2005 | pmid = 16135466 | doi = 10.1200/JCO.2005.04.127 }}</ref>。

==結構==
恩博是由兩種天然的人體蛋白質結合而成的合成蛋白，當中包括了75 kD的可溶性TNF受體和人類[[IgG|免疫球蛋白IgG1]]的{{tsl|en|Fragment crystallizable region|可結晶區域片段|Fc}}區段<ref name="pmid1936291">{{cite journal | vauthors = Smola MG, Soyer HP, Scharnagl E | title = Surgical treatment of dermatofibrosarcoma protuberans. A retrospective study of 20 cases with review of literature | journal = European Journal of Surgical Oncology | volume = 17 | issue = 5 | pages = 447–53 | date = October 1991 | pmid = 1936291 }}</ref>。上述兩種分子經由基因工程結合而形成一個雙體融合蛋白<ref name="pmid1936291" />。恩博是個複雜的分子，結構中包含6個N-多醣基、至多14個O-多醣基和29個雙硫架橋<ref>{{cite journal | vauthors = Houel S, Hilliard M, Yu YQ, McLoughlin N, Martin SM, Rudd PM, Williams JP, Chen W | title = N- and O-glycosylation analysis of etanercept using liquid chromatography and quadrupole time-of-flight mass spectrometry equipped with electron-transfer dissociation functionality | journal = Analytical Chemistry | volume = 86 | issue = 1 | pages = 576–84 | date = January 2014 | pmid = 24308717 | doi = 10.1021/ac402726h }}</ref><ref>{{Cite journal|title=Solution of the structure of the TNF-TNFR2 complex|url=https://www.ncbi.nlm.nih.gov/pubmed/21081755|last=Mukai|first=Yohei|last2=Nakamura|first2=Teruya|date=2010-11-16|journal=Science Signaling|issue=148|doi=10.1126/scisignal.2000954|volume=3|pages=ra83|issn=1937-9145|pmid=21081755|last3=Yoshikawa|first3=Mai|last4=Yoshioka|first4=Yasuo|last5=Tsunoda|first5=Shin-ichi|last6=Nakagawa|first6=Shinsaku|last7=Yamagata|first7=Yuriko|last8=Tsutsumi|first8=Yasuo}}</ref><ref>{{Cite journal|title=The structure-function relationship of disulfide bonds in etanercept|author=|url=https://www.ncbi.nlm.nih.gov/pubmed/28638112|last=Lamanna|first=William C.|last2=Mayer|first2=Robert Ernst|date=06 21, 2017|journal=Scientific Reports|issue=1|doi=10.1038/s41598-017-04320-5|others=|year=|volume=7|page=|pages=3951|issn=2045-2322|pmc=5479810|pmid=28638112|last3=Rupprechter|first3=Alfred|last4=Fuchs|first4=Michael|last5=Higel|first5=Fabian|last6=Fritsch|first6=Cornelius|last7=Vogelsang|first7=Cornelia|last8=Seidl|first8=Andreas|last9=Toll|first9=Hansjoerg}}</ref>。

==相似藥物==
* 可溶性抗腫瘤壞死因子受體
** {{tsl|en|Pegsunercept|Pegsunercept}}
* 抗腫瘤壞死因子[[單株抗體|單株抗體]]
** {{tsl|en|Infliximab|Infliximab}}
** {{tsl|en|Adalimumab|Adalimumab}}
** {{tsl|en|Certolizumab pegol|Certolizumab pegol}}
** {{tsl|en|Golimumab|Golimumab}}

== 參考資料 ==
{{reflist}}

== 外部連結 ==
{{commons category|Etanercept}}
* [http://www.enbrel.com/ 安进生技公司的恩博介紹頁面]

{{Immunosuppressants}}

[[Category:免疫抑制剂|Category:免疫抑制剂]]
[[Category:惠氏|Category:惠氏]]